869494-03-1 (N-乙基-N'-[7-(3-氟-2-吡啶基)-5-[2-(1-羟基-1-甲基乙基)-5-嘧啶基]-1H-苯并咪唑-2-基]脲,N-Ethyl-N'-[7-(3-fluoro-2-pyridinyl)-5-[2-(1-hydroxy-1-methylethyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]urea)

CAS号:
869494-03-1
中文名称:
N-乙基-N'-[7-(3-氟-2-吡啶基)-5-[2-(1-羟基-1-甲基乙基)-5-嘧啶基]-1H-苯并咪唑-2-基]脲
英文名称:
N-Ethyl-N'-[7-(3-fluoro-2-pyridinyl)-5-[2-(1-hydroxy-1-methylethyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]urea
分子式:
C22H22FN7O2
分子量:
435.454186916351

N-乙基-N'-[7-(3-氟-2-吡啶基)-5-[2-(1-羟基-1-甲基乙基)-5-嘧啶基]-1H-苯并咪唑-2-基]脲(869494-03-1)名称与标识符

名称

英文别名:
H. influenzae MIC (μg/mL);E. faecalis MIC (μg/mL);S. pneumoniae MIC (μg/mL);E. coli Gyrase Ki (nM);S. aureus TopoIV Ki (nM);S. aureus MIC + HS (μg/mL);S. aureus MIC (μg/mL);N-Ethyl-N′-[7-(3-fluoro-2-pyridinyl)-5-[2-(1-hydroxy-1-methylethyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]urea (ACI);Urea, N-ethyl-N′-[4-(3-fluoro-2-pyridinyl)-6-[2-(1-hydroxy-1-methylethyl)-5-pyrimidinyl]-1H-benzimidazol-2-yl]- (9CI);

标识符

InChIKey:
DCQDWORRDTVBGL-UHFFFAOYSA-N
Inchi:
1S/C22H22FN7O2/c1-4-24-21(31)30-20-28-16-9-12(13-10-26-19(27-11-13)22(2,3)32)8-14(18(16)29-20)17-15(23)6-5-7-25-17/h5-11,32H,4H2,1-3H3,(H3,24,28,29,30,31)
SMILES:
O=C(NCC)NC1NC2C(=CC(C3C=NC(C(C)(C)O)=NC=3)=CC=2C2C(F)=CC=CN=2)N=1

N-乙基-N'-[7-(3-氟-2-吡啶基)-5-[2-(1-羟基-1-甲基乙基)-5-嘧啶基]-1H-苯并咪唑-2-基]脲(869494-03-1)推荐厂家 更多厂家(1)

公司名称手机号/电话联系人QQ微信询单
上海楷森生物科技有限公司 17558870519
175-58870519
赵经理 3003926540
询单

N-乙基-N'-[7-(3-氟-2-吡啶基)-5-[2-(1-羟基-1-甲基乙基)-5-嘧啶基]-1H-苯并咪唑-2-基]脲(869494-03-1)合成路线

合成路线:1 步
反应条件:
参考文献:
Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability
Grillot, Anne-Laure; et al, Journal of Medicinal Chemistry, 2014, 57(21), 8792-8816
合成路线:1 步
反应条件:
参考文献:
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy
Perola, Emanuele; et al, Bioorganic & Medicinal Chemistry Letters, 2014, 24(9), 2177-2181
合成路线:2 步
反应条件:
参考文献:
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy
Perola, Emanuele; et al, Bioorganic & Medicinal Chemistry Letters, 2014, 24(9), 2177-2181
合成路线:3 步
反应条件:
参考文献:
Second-Generation Antibacterial Benzimidazole Ureas: Discovery of a Preclinical Candidate with Reduced Metabolic Liability
Grillot, Anne-Laure; et al, Journal of Medicinal Chemistry, 2014, 57(21), 8792-8816